

Developing novel technologies and tools for Cancer therapeutics & diagnostics

Wednesday, 19 May 2004, Institute of Physics

The patient pool available for cancer therapies is rising in line with an ageing global population, dwarfing other major pharmaceutical markets and driving the commercial importance for oncology products. Despite a predicted slow-down in the global cancer market's growth over the next five years, the innovative cancer therapy class is forecast to more than triple in value. These constantly changing dynamics within this highly competitive segment require innovative approaches to overcome the unique challenges of cancer drug development:

- ★ How can pharma and biotech companies tackle the maturity of the cytotoxic and hormonal markets due to increasing generic competition?
- ★ How can academia and biotech companies help big pharmaceutical companies avoid over-reliance on the sales of only a few blockbusters?
- ★ How can closer interactions between the various sectors of the industry meet the need for a strong R&D pipeline to sustain revenues?

18:00 – 18:30 Registration with tea and coffee

**18:30 – 18:40 Introduction to aims and objectives of LTN by
Dr Helen Abbott, *Technology Consultant*, LONDON TECHNOLOGY NETWORK**

18:40 – 20:00 Speaker presentations and Q&A

**20:00 – 21:00 Wine reception & buffet – networking opportunity and poster sessions from
London's universities showcasing the latest cancer research**

- 1. Introduction from the chair: determining the latest research issues in cancer research**
Professor Richard Begent, *Head, Department of Oncology, Royal Free and University College Medical School*, UNIVERSITY COLLEGE LONDON
- 2. Highlighting the most important cancer therapies & technologies to direct research activity**
 - Investigating available drugs in the market and assessing tools for the value of therapies
 - Examining symptomatic versus disease modifying cancer therapies
 - Clarifying how academic cancer research can be directed to meet industry needs
 - Emphasising potential academic input at all stages of drug discovery and drug development**Dr Johann De Bono, *Senior Lecturer and Honorary Consultant in Medical Oncology, Royal Marsden Hospital*, INSTITUTE OF CANCER RESEARCH**
- 3. Examining how to direct cancer research to meet business requirements from a biotech company's perspective**
 - Investigating UK R&D drivers and assessing the commercial potential for emerging technologies
 - Enhancing effectiveness of existing therapies and technologies
 - Determining challenges of new technologies such as genomics and proteomics
 - Evaluating the routes of securing technical innovation from academia**Glyn Edwards, *Chief Executive Officer*, ANTISOMA RESEARCH LTD**
- 4. Investigating how universities and biotech companies can fill the gaps in the development pipeline for pharma companies**
 - Establishing how academic cancer research can produce targets for drug discovery
 - Improving ways to identify the right patients to match compounds
 - Determining where academia and biotech fit into cancer research projects in a large pharma company
 - Highlighting current collaborative projects in cancer research**Dr Campbell Wilson, *Director, Discovery Alliances, Cancer & Infection Research*, ASTRAZENECA**
- 5. Question and answer session from the audience with the speaker panel**

All events are by INVITATION ONLY

Speaker profiles

Helen Abbott – LONDON TECHNOLOGY NETWORK

Helen has a first degree in Physiology and Biochemistry and a PhD in Molecular Immunology. She originally spent 4 years working in drug development in the pharmaceutical industry - variously for Chiltern International, Pasteur Merieux (now Aventis Pasteur) and the top ten pharma company Sandoz (now Novartis) before joining the specialist life science consulting group Technomark. Helen worked with a variety of pharma, biotech, investment and public sector clients in projects spanning multiple therapeutic and technology areas. Helen is also currently in the final year of an executive MBA at London Business School.

Richard Begent – UNIVERSITY COLLEGE LONDON

Richard has been Head of the Department of Oncology at Royal Free and University College Medical School since 1990. From 1980 until 1990, he was Honorary Consultant Physician at Charing Cross Hospital, and from 1987, Gibb Research Fellow of the Cancer Research Campaign. His research interests include improving the understanding of cancer and the care of people with the disease, targeted cancer therapy and imaging, treatment of gastrointestinal cancer, germ cell tumours and lymphoma, as well as bioinformatics and mathematical modelling in cancer therapy.

Johann De Bono – INSTITUTE FOR CANCER RESEARCH

Johann was appointed as Senior Lecturer and Honorary Consultant in Medical Oncology at the Royal Marsden Hospital and Institute of Cancer Research in July 2003. He directs the clinical drug development Phase I trials programme at the Royal Marsden Hospital with a particular interest in the pharmacokinetic-pharmacodynamic evaluation of targeted therapeutics and pharmacogenetics. Johann graduated in medicine with distinctions from the University of Glasgow in Scotland in 1989. He was awarded a four-year Cancer Research UK Clinical Research Scholarship, which allowed him to pursue a PhD studying the regulation of epithelial stem cell proliferation at the Beatson Institute for Cancer Research in Glasgow.

Glyn Edwards - ANTISOMA

Glyn joined Antisoma as Chief Executive Officer in March 1998. He has led the company through an IPO on Nasdaq Europe and a listing on the LSE. He is an Executive Director of Antisoma plc, Antisoma Research Ltd, and Cancer Therapeutics Ltd, as well as a Director of Elara Associates Limited. Prior to joining Antisoma, he was Director of Business Development at Therapeutic Antibodies. Glyn has a BSc in Biochemistry from the University of Bristol and is a graduate of London Business School.

Campbell Wilson - ASTRAZENCA

Campbell is Director of Discovery Alliances at AstraZeneca based at Alderley Park Cheshire. He is responsible for the negotiation and management of strategic alliances and pre-clinical licensing within the cancer and infection therapeutic areas, on a global basis. Campbell obtained his BSc from Edinburgh University and PhD from Cardiff. He worked in cardiovascular research at Beecham Pharmaceuticals then at ICI/Zeneca before changing career paths in 1996.

See what participants said about previous LTN events:

“I found the event extremely stimulating, it was good to get different viewpoints and I will be making arrangements to visit some of the departments in the near future”

Mel Pullen, *Chief Systems Architect, SYMBIAN*

“I was particularly pleased to see that there appeared to be a lot of industrialists at this event who had not attended any previous LTN events”

Dr Martin Bush, *Senior Lecturer, SOUTHBANK UNIVERSITY*

“Good quality of delegates and speakers”.

Anthony Holmes, *Professional Services, IMAGE METRICS PLC*

All events are by INVITATION ONLY

LTN's Mission:


To help technology-intensive companies be more effective and efficient in their “knowledge acquisition” from London’s universities.

Each month, London Technology Network brings together industrial and academic thought leaders in the most powerful new technologies, both on the stage and in the audience. LTN discussions identify common technology platforms shared across industries and disciplines, and explore how industry, government and academia can collaborate to introduce and exploit these technologies. Attendees build personal networks that foster efficient transfer of technology and drive down the cost and time to deliver new products to market.

How to get to the Institute of Physics

The LTN event will take place at the Institute of Physics, London W1B 1NT, Telephone: 020 7470 4800, indicated by the yellow star below:

For further information go to <http://www.kcl.ac.uk/maps/guys.html> or <http://www.streetmap.co.uk>.



Nearest tube stations

Goodge Street
(Northern line)

Great Portland Street
(Metropolitan, Circle and Hammersmith & City lines)

Oxford Circus
(Bakerloo and Victoria lines)

Regent's Park
(Bakerloo line)

Warren Street
(Northern and Victoria lines)